

New Technologies for HPAPI Manufacturing and Containment

Focus on new technology at the 2019 HPAPI USA Conference

LONDON, UNITED KINGDOM, August 29, 2019 /EINPresswire.com/ -- SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production.

At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures.

Key highlights include:

Alternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing

- Alternative drug manufacture through nanocrystal formulations, thin films and hot-melt extrusion/injection moulding that reduces HPAPI powder exposure and improve safety
- Detailing step-by-step process along with the equipment needed to achieve these alternative HPAPI manufacturing techniques
- The advantages of continuous manufacturing utilizing alternative manufacturing technologies

Respiratory HPAPIs: development, formulation and delivery

- Advantages and targets of a respiratory HPAPI

SMI Presents the Inaugural Event

Highly Potent Active Pharmaceutical Ingredients BOSTON, USA



**OCTOBER
21-22, 2019**

WWW.HPAPI-USA.COM

HPAPI USA 2019

- Equipment and analytical instruments that are most suitable for respiratory containment and safe handling
- Strategies for the development and industrialization process to ensure respiratory HPAPI success
- The current trends in respiratory HPAPIs

Training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management

- Staff training - understanding the equipment they are using
- Due diligence for management to continually assess the HPAPI workspace and keeping operators up to date
- Understand the need to establish expectations surrounding the safe handling of HPAPI

www.hpapi-usa.com/PR5

Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA

Conference: October 21st – 22nd

Workshops: October 23rd

Venue: Sheraton Boston Hotel, USA

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or fbegum@smi-online.co.uk

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 or nhoward@smi-online.co.uk

Neill Howard
SMi Group Ltd
+44 20 7827 6000
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/494916005>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.